Literature DB >> 26228644

Low Bone Turnover in Chronic Kidney Disease Is Associated with Decreased VEGF-A Expression and Osteoblast Differentiation.

Neal X Chen1, Kalisha D O'Neill, Matthew R Allen, Christopher L Newman, Sharon M Moe.   

Abstract

BACKGROUND: Low turnover bone (low bone formation rates (BFRs)) with decreased osteoblast number is common in patients with chronic kidney disease (CKD) and attributed to 'over-suppression' of the parathyroid hormone (PTH) despite supra-physiologic levels. An alternative hypothesis is abnormal osteoblast differentiation, resulting in low BFRs due to reduced VEGF-A.
METHODS: We analyzed the expression of VEGF-A and mesenchymal stem cell (MSC) differentiation factors in freshly isolated bone marrow (BM) cells, and in BM cell-derived MSC in rats with different levels of BFRs and PTH (modulated by calcium and zoledronic acid). The regulators of VEGF in MSC were also determined.
RESULTS: VEGF-A expression was reduced in the BM cells from CKD vs. normal animals (p < 0.02). In BM-derived MSC from CKD, there were decreased osteoblast transcription factors and mineralization. In CKD animals, the BM VEGF-A expression was positively correlated with BFR (r = 0.80, p < 0.001). Reducing BFRs in CKD animals led to reductions in VEGF-A expression and osteoblast transcription factors regardless of the PTH level. We therefore examined other regulators of VEGF-A and found decreased expression of hypoxia-inducible factor-1α and the master transcription factor of antioxidants nuclear factor (erythroid-derived 2)-like 2 in CKD animals with low PTH.
CONCLUSION: Low BFRs in CKD are associated with a basal decrease in VEGF-A expression in BM that may be driven by altered hypoxia and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26228644     DOI: 10.1159/000438461

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  9 in total

1.  Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility.

Authors:  Keith G Avin; Julian A Vallejo; Neal X Chen; Kun Wang; Chad D Touchberry; Marco Brotto; Sarah L Dallas; Sharon M Moe; Michael J Wacker
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-20       Impact factor: 4.310

2.  Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Authors:  Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White
Journal:  JCI Insight       Date:  2019-02-21

3.  Phosphate binders usage, patients knowledge, and adherence. A cross-sectional study in 4 centers at Qassim, Saudi Arabia.

Authors:  Alanoud M Aleidi; Nouf J Alayed; Htoon M Alduraibi; Najd S Alqassimi; Amal A Ismail
Journal:  Saudi Med J       Date:  2020-10       Impact factor: 1.484

Review 4.  Transcriptomics: a Solution for Renal Osteodystrophy?

Authors:  Aline Martin; Valentin David
Journal:  Curr Osteoporos Rep       Date:  2020-06       Impact factor: 5.096

5.  MicroRNAs 223-3p and 93-5p in patients with chronic kidney disease before and after renal transplantation.

Authors:  M Ulbing; A H Kirsch; B Leber; S Lemesch; J Münzker; N Schweighofer; D Hofer; O Trummer; A R Rosenkranz; H Müller; K Eller; V Stadlbauer; B Obermayer-Pietsch
Journal:  Bone       Date:  2016-11-17       Impact factor: 4.398

6.  Timing of geranylgeraniol addition increases osteoblast activities under alendronate condition.

Authors:  Harikarn Mungpayabarn; Somying Patntirapong
Journal:  J Oral Biol Craniofac Res       Date:  2021-05-05

Review 7.  Osteogenic Differentiation in Healthy and Pathological Conditions.

Authors:  Maria Teresa Valenti; Luca Dalle Carbonare; Monica Mottes
Journal:  Int J Mol Sci       Date:  2016-12-27       Impact factor: 5.923

8.  Skeletal vascular perfusion is altered in chronic kidney disease.

Authors:  Mohammad W Aref; Elizabeth A Swallow; Neal X Chen; Sharon M Moe; Matthew R Allen
Journal:  Bone Rep       Date:  2018-05-04

Review 9.  The molecular mechanisms of hemodialysis vascular access failure.

Authors:  Akshaar Brahmbhatt; Andrea Remuzzi; Marco Franzoni; Sanjay Misra
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.